Gene · 55869
Papers3,134
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
1,201 to 1,220 of 3,134
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Integration of transcriptomic, proteomic and metabolomic data to reveal the biological mechanisms of AAI injury in renal epithelial cells. | Toxicol In Vitro | 2021 | 33212167 | PubTator, text mining | PubMed |
| Histone deacetylase 8 inhibition suppresses mantle cell lymphoma viability while preserving natural killer cell function. | Biochem Biophys Res Commun | 2021 | 33190829 | PubTator, text mining | PubMed |
| Effects of signaling pathway inhibitors on hematopoietic stem cells. | Mol Med Rep | 2021 | 33179097 | PubTator, text mining | PubMed |
| Effect of 3-subsitution of quinolinehydroxamic acids on selectivity of histone deacetylase isoforms. | J Enzyme Inhib Med Chem | 2021 | 33161799 | PubTator, text mining | PubMed |
| Therapeutic Vulnerabilities of Transcription Factors in AML. | Mol Cancer Ther | 2021 | 33158995 | PubTator, text mining | PubMed |
| Molecular targeting therapies for neuroblastoma: Progress and challenges. | Med Res Rev | 2021 | 33155698 | PubTator, text mining | PubMed |
| HPV+ve/-ve oral-tongue cancer stem cells: A potential target for relapse-free therapy. | Transl Oncol | 2021 | 33129107 | PubTator, text mining | PubMed |
| Analysis of laboratory reporting practices using a quality assessment of a virtual patient. | Genet Med | 2021 | 33122805 | PubTator, text mining | PubMed |
| Identification of histone deacetylase inhibitors with (arylidene)aminoxy scaffold active in uveal melanoma cell lines. | J Enzyme Inhib Med Chem | 2021 | 33100043 | PubTator, text mining | PubMed |
| Alternative genomic diagnoses for individuals with a clinical diagnosis of Dubowitz syndrome. | Am J Med Genet A | 2021 | 33098347 | PubTator, text mining | PubMed |
| Epigenetic regulation of somatostatin and somatostatin receptors in neuroendocrine tumors and other types of cancer. | Rev Endocr Metab Disord | 2021 | 33085037 | PubTator, text mining | PubMed |
| DUSP16 is a regulator of human hematopoietic stem and progenitor cells and promotes their expansion ex vivo. | Leukemia | 2021 | 33077868 | PubTator, text mining | PubMed |
| Tailored Quinolines Demonstrate Flexibility to Exert Antitumor Effects through Varied Mechanisms-A Medicinal Perspective. | Anticancer Agents Med Chem | 2021 | 32900354 | PubTator, text mining | PubMed |
| Noncanonical EphA2 Signaling Is a Driver of Tumor-Endothelial Cell Interactions and Metastatic Dissemination in BRAF Inhibitor‒Resistant Melanoma. | J Invest Dermatol | 2021 | 32890629 | PubTator, text mining | PubMed |
| Isoflurane promotes proliferation of squamous cervical cancer cells through mTOR-histone deacetylase 6 pathway. | Mol Cell Biochem | 2021 | 32833118 | PubTator, text mining | PubMed |
| Role of histone deacetylases in bone development and skeletal disorders. | Bone | 2021 | 32829038 | PubTator, text mining | PubMed |
| Histone deacetylase 3 promotes innate antiviral immunity through deacetylation of TBK1. | Protein Cell | 2021 | 32772249 | PubTator, text mining | PubMed |
| Epigenetic Evaluation of N-(2-hydroxyphenyl)-2-Propylpentanamide, a Valproic Acid Aryl Derivative with Activity Against HeLa Cells. | Curr Mol Pharmacol | 2021 | 32744980 | PubTator, text mining | PubMed |
| Regulation of histone deacetylase activities and functions by phosphorylation and its physiological relevance. | Cell Mol Life Sci | 2021 | 32683534 | PubTator, text mining | PubMed |
| Investigation of HDAC8-ligands' intermolecular forces through molecular dynamics simulations: profiling of non-bonding energies to design potential compounds as new anti-cancer agents. | J Biomol Struct Dyn | 2021 | 32578494 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/55869/papers?page=61